Evidence map›Paper›PMID 30977255›Full record

ReviewStem cells (Dayton, Ohio)2019

Concise Review: Mesenchymal Stem Cells: From Roots to Boost.

Anna Andrzejewska, Barbara Lukomska, Miroslaw Janowski

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells (Dayton, Ohio), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 344 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
344citing papers in PubMed, 1 pooled it
42.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

344 citing papers in PubMed, 1 synthesis or guideline pooled it, 614 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

284 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Anna AndrzejewskaNeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Barbara LukomskaNeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Miroslaw JanowskiNeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0001-5261-7975
Mossakowski Medical Research Institute, Polish Academy of Sciences · PLJohns Hopkins University · US

Funding

Image-Guided Stem Cell Therapy of Perinatal Asphyxia in a Large Animal ModelR01NS091100 · NINDS · JOHNS HOPKINS UNIVERSITY · PI JANOWSKI, MIROSLAW · 2015 to 2019
$1.8M
NINDS NIH HHS R01 NS091100
6 · The paper itself

Abstract

It was shown as long as half a century ago that bone marrow is a source of not only hematopoietic stem cells, but also stem cells of mesenchymal tissues. Then the term "mesenchymal stem cells" (MSCs) was coined in the early 1990s, and more than a decade later, the criteria for defining MSCs have been released by the International Society for Cellular Therapy. The easy derivation from a variety of fetal and adult tissues and undemanding cell culture conditions made MSCs an attractive research object. It was followed by the avalanche of reports from preclinical studies on potentially therapeutic properties of MSCs, such as immunomodulation, trophic support and capability for a spontaneous differentiation into connective tissue cells, and differentiation into the majority of cell types upon specific inductive conditions. Although ontogenesis, niche, and heterogeneity of MSCs are still under investigation, there is a rapid boost of attempts at clinical applications of MSCs, especially for a flood of civilization-driven conditions in so quickly aging societies, not only in the developed countries, but also in the populous developing world. The fields of regenerative medicine and oncology are particularly extensively addressed by MSC applications, in part due to the paucity of traditional therapeutic options for these highly demanding and costly conditions. There are currently almost 1,000 clinical trials registered worldwide at ClinicalTrials.gov, and it seems that we are starting to witness the snowball effect with MSCs becoming a powerful global industry; however, the spectacular effects of MSCs in the clinic still need to be shown. Stem Cells 2019;37:855-864.

Indexed as

Mesenchymal Stem Cell TransplantationAdipocytesAdultAnimalsBone Marrow CellsCell- and Tissue-Based TherapyCell CommunicationCell Culture TechniquesCell DifferentiationCell ProliferationChondrocytesHumansImmunomodulationMesenchymal Stem CellsNeuronsOsteoblastsClinicalDifferentiationHistoryImmunomodulationMesenchymal stem cellsParacrine activity

Identifiers

PMID30977255
PMCPMC6658105
OpenAlexW2943914150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.